Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 2010 Aug;31(8):381-90. doi: 10.1016/j.tips.2010.05.004. Epub 2010 Jun 25.

Signaling pathways in schizophrenia: emerging targets and therapeutic strategies.

Author information

1
Department of Psychiatry, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA.

Abstract

Dopamine D(2) receptor antagonism is a unifying property of all antipsychotic drugs in use for schizophrenia. While often effective at ameliorating psychosis, these drugs are largely ineffective at treating negative and cognitive symptoms. Increasing attention is being focused on the complex genetics of the illness and the signaling pathways implicated in its pathophysiology. We review targeted approaches for pharmacotherapy involving the glutamatergic, GABAergic and cholinergic pathways. We also describe several of the major genetic findings that identify signaling pathways representing potential targets for novel pharmacological intervention. These include genes in the 22q11 locus, DISC1, Neuregulin 1/ErbB4, and components of the Akt/GSK-3 pathway.

PMID:
20579747
PMCID:
PMC3635536
DOI:
10.1016/j.tips.2010.05.004
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center